Vasculotide TFA
Based on 1 Customer Validation
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.
For research use only. We do not sell to patients.
- Purity: 99.88%
- Molecular Weight:14000 (average)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Vasculotide (28 ng/mL; 3 h) TFA enhances the clonogenic survival rate of irradiated HMVEChTERT cells, with a significant SER value of 1.17[2].
Vasculotide (28 ng/mL; 3 h) TFA preserves the angiogenic capacity of HMVEChTERTs exposed to 4 Gy irradiation, resulting in the formation of tubules comparable to those of non-irradiated cells[2].
Vasculotide (15 min) TFA stimulates the phosphorylation of Tie2 receptors in HMVEChTERTs and activates the downstream AKT pro-survival pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Vasculotide (10 μg/kg; intraperitoneal injection; administered 24 h and 1.5 h prior to irradiation, followed by once every other day for 28 consecutive days) TFA reduces acute cutaneous radiation injury in mice, as evidenced by a 43% reduction in the total area of severe desquamation wounds, alleviated inflammatory responses, and improved wound healing[2].
Vasculotide (10 μg/kg; i.p.; pre-irradiation only, continuous administration, post-irradiation only; total 26 days) TFA reduces acute cutaneous radiation injury in mice exposed to 35 Gy irradiation when administered via all tested regimens (pre-irradiation, continuous administration, post-irradiation) TFA, among which the post-irradiation regimen significantly decreases the overall skin injury score by 28%[2].
Vasculotide (250 ng; intraperitoneal injection; once every 48 hours; for 3 months) TFA reduces the superharmonic threshold pressure for focused ultrasound (FUS)-induced blood-brain barrier (BBB) permeability by 21-29% in TgCRND8 mice and accelerates BBB repair, with an 87% BBB closure rate observed 20 hours after FUS treatment in this Alzheimer's disease model[3].
Adjuvant therapy with Vasculotide (500 ng; intravenous injection; 2 administrations) TFA combined with Ampicillin (HY-B0522) significantly reduces pulmonary permeability, ventilator-induced lung injury (VILI)-related histological damage and edema formation in mice with mechanically ventilated Streptococcus pneumoniae pneumonia, without affecting immune responses or bacterial loads[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 14000 (average)
-
Color Colorless to off-white
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 25 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (Need ultrasonic)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dekker NAM, et al. Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats. Br J Anaesth. 2018;121(5):1041-1051. [Content Brief]
[2]. Korpela E, et al. Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model. BMC Cancer. 2014;14:614. Published 2014 Aug 26. [Content Brief]
[3]. Lynch M, et al. Vasculotide restores the blood-brain barrier after focused ultrasound-induced permeability in a mouse model of Alzheimer's disease. Int J Med Sci. 2021;18(2):482-493. Published 2021 Jan 1. [Content Brief]
[4]. Lask A, et al. Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice. Sci Rep. 2022;12(1):15531. Published 2022 Sep 15. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vasculotide TFA Related Classifications
HY-P10580A Related Classifications
Powered by Bioz